New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
10:16 EDTWTW, AVP, TRLA, EXPE, MACKOptions with decreasing implied volatility: MACK EXPE TRLA AVP WTW
News For MACK;EXPE;TRLA;AVP;WTW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
09:10 EDTEXPEExpedia coverage assumed with a Neutral at Credit Suisse
Target $87.
November 21, 2014
10:47 EDTEXPEAmazon reported travel entry viewed positively by Piper's Munster
Subscribe for More Information
08:25 EDTMACKMerrimack presents data from Phase 1 studies of MM-398, MM-151
Merrimack Pharmaceuticals announced data from multiple presentations. Data presented includes the first public presentation on the preclinical activity and potency of MM-131, and preclinical and clinical data on MM-151. An additional abstract details Phase 1 results from a clinical pilot study evaluating the feasibility of using ferumoxytol, an iron oxide nanoparticle, as a proxy to determine tumor responses to MM-398, nanoliposomal irinotecan. Computational modeling predicted that MM-131 would block HGF from binding to c-Met with higher potency through concurrent binding to epithelial cell adhesion molecule, an abundant protein on the cell surface of many cancer types. The models also suggested that the potency of MM-131 would increase with higher levels of EpCAM, as binding to EpCAM enables MM-131 to concentrate at the cell surface and effectively compete with HGF binding to c-Met. Preclinical studies validated this prediction and MM-131 was shown to inhibit HGF-mediated pathway activation and both the growth and migration of tumor cells across a panel of cell lines in vitro. Additionally, MM-131 inhibits tumor growth in models of c-Met-driven cancer in vivo. Overall, ferumoxytol was well tolerated. Adverse events of MM-398 therapy were consistent with previous studies, and no adverse events were directly attributable to ferumoxytol.
November 20, 2014
05:20 EDTMACKPharmaEngine, Merrimack receive FDA fast track designation for MM-398
PharmaEngine and its partner Merrimack Pharmaceuticals (MACK) announced that MM-398 has been granted the Fast Track designation by the FDA for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Merrimack expects to begin the NDA submission in 2014.
November 19, 2014
16:31 EDTAVPOn The Fly: Closing Wrap
Subscribe for More Information
09:16 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTMACKMerrimack receives FDA fast track designation for MM-398
Subscribe for More Information
November 18, 2014
17:09 EDTAVPAvon Products announces actions to reduce costs including headcount reductions
Subscribe for More Information
14:01 EDTEXPEExpedia to begin selling airline branded fares in 2015
Subscribe for More Information
07:20 EDTMACKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 14, 2014
17:13 EDTEXPEAppaloosa gives quarterly update on stakes
NEW STAKES: NXP Semiconductors (NXPI), Lorillard (LO), Alibaba (BABA), and Shire (SHPG). INCREASED STAKES: Whirlpool (WHR), Priceline (PCLN), Delta (DAL), CBS (CBS), and General Motors (GM). DECREASED STAKES: American Airlines (AAL), Disney (DIS), Apple (AAPL), MGM Resorts (MGM), and Eastman Chemical (EMN). LIQUIDATED STAKES: Expedia (EXPE), AIG (AIG), Prudential (PRU), Celanese (CE), and ASML Holding (ASML).
10:03 EDTAVPHigh option volume stocks
Subscribe for More Information
November 13, 2014
09:15 EDTMACKMerrimack to present advances on targeted cancer molecules
Merrimack Pharmaceuticals announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
November 11, 2014
08:05 EDTMACKMerrimack shares should be bought on weakness, says Oppenheimer
After Merrimack announced a delay of about one quarter for the NDA submission of its MM-398, Oppenheimer's concern about the issue is limited. The firm says that the FDA appears to be interested in ensuring that MM-398 has extended nanoparticle stability, but does not appear to have identified a material deficit in the company's chemistry, manufacturing, and controls. Oppenheimer keeps an $11 price target and Outperform rating on Merrimack.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use